MDM2 and non-small cell lung carcinoma: Kim et al. (Paez et al. 2004) confirmed that advanced NSCLC patients harboring sensitive EGFR mutations and MDM2 amplification had a shorter PFS during EGFR-TKIs treatment than patients without MDM2 amplification (6.6 versus 10.4 months; P = 0.025).